IL25 and breast carcinoma: Intravenous or intraperitoneal administration of IL-17E (IL-25) in a variety of xenograft tumor models, including breast cancer, showed an antitumoral activity alone or in combination with chemotherapy or immunotherapy due to the induction of eosinophil expansion, through the production of IL-5 [58].